Alkermes reports financial results for first one fourth of 2014 Alkermes plc today reported financial outcomes for the first one fourth of 2014. ‘Through the one fourth, we continued to create positive cashflow, reflecting the strength of our industrial business and enabling us to invest in our advancing late-stage pipeline and prepare for the release of aripiprazole lauroxil,’ commented James Frates, Chief Financial Officer of Alkermes. ‘With an increase of than $700 million in money and investments and a cash-generating industrial portfolio, Alkermes is well-positioned to build our business. The business continues to perform as we planned, today we are reiterating the financial targets for 2014 that we provided in February and.’ ‘In early April, we announced the positive phase 3 data for aripiprazole lauroxil.Addiction-treatment centers was about 76 %, compared with less than 18 % in the general population. Everyone who enters drug abuse treatment must have their tobacco make use of evaluated and treated, Guydish said. If indeed they don’t want to be treated and quit right away, they should have some scholarly education to greatly help them think more about quitting. He noted that a number of research strongly suggest that addressing individuals’ smoking can enhance the end result of their substance abuse treatment.